Understanding how deadly lung cancers control the local immune …
23 hours ago · Lung cancer is the leading cause of cancer-related death in the U.S., accounting for about 1 in 5 of all cancer deaths, according to the American Cancer Society.
Understanding How Deadly Lung Cancers Control the Local …
1 day ago · Northwestern Medicine scientists have discovered how a protein in a deadly type of lung cancer can control how the immune system responds to the tumor, according to a study published in the Proceedings of the National Academy of Sciences. Lung cancer is the leading cause of cancer-related death in the U.S., accounting for about 1 in 5 of all ...
FDA Expands Approval of Opdivo in Early-Stage Lung Cancer
3 days ago · Lung Cancer. Lung Cancer Treatment. The U.S. Food and Drug Administration (FDA) has expanded approval for nivolumab (Opdivo) to include neoadjuvant treatment combined with platinum-doublet chemotherapy followed by single-agent nivolumab adjuvant treatment of resectable, EGFR and ALK- negative, early-stage non-small cell lung cancer (NSCLC).
Lung Cancer News -- ScienceDaily
4 days ago · Information about lung cancer symptoms and treatments. Explore the latest medical research on cancers including experimental treatments.
Lung cancer survival rates are up thanks to immunotherapy, other ... - NPR
Apr 12, 2024 · Lung cancer remains the most lethal form of the disease, killing about 135,000 Americans a year – more than breast, prostate and colon cancer combined – which is why many people still think of...
Targeted Drug Stops Lung Cancer Growth for Five Years in Over …
Jun 13, 2024 · A study shows that a targeted therapy drug stops the spread of lung cancer for 5 years or more. The drug, lorlatinib (Lobrena), also stops new cancer growth in the brain. These benefits were seen in 3 out of every 5 people with advanced non-small cell lung cancer (NSCLC) with an ALK gene mutation.
Lung cancer treatment produces progression-free survival results …
Jun 5, 2024 · The positive results from the LAURA Phase III trial underscore the importance of early testing and diagnosis in lung cancer, which remains the leading cause of cancer death worldwide,...
US lung cancer survival rates rise, but it’s still the leading ... - CNN
Nov 14, 2023 · Over the past five years, the five-year survival rate for lung cancer in the US has increased a significant 22%, according to a new report from the American Lung Association.
Osimertinib Improves Survival in Lung Cancer - NCI
Jul 5, 2023 · Improved overall survival with osimertinib. The initial results from ADAURA, published in October 2020, offered signs of possible survival improvements with adjuvant osimertinib. This treatment, they showed, dramatically improved how long people lived without any evidence of their cancer returning.
Adjuvant Immunotherapy Approved for Lung Cancer - NCI
Oct 26, 2021 · FDA has approved the immunotherapy atezolizumab (Tecentriq) as an additional, or adjuvant, treatment for some patients with non-small cell lung cancer (NSCLC). With the approval, atezolizumab becomes the first checkpoint inhibitor approved as an adjuvant treatment for lung cancer.
- Some results have been removed